StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note published on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 1.9 %
Titan Pharmaceuticals stock opened at $4.06 on Thursday. The company has a fifty day simple moving average of $3.45 and a 200-day simple moving average of $4.51. Titan Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- 5 discounted opportunities for dividend growth investors
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- How to Effectively Use the MarketBeat Ratings Screener
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Consumer Discretionary Stocks Explained
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
